

## RAAJ MEDISAFE INDIA LIMITED

Regd. Office: 75/2 & 3, Industrial Area, Maksi Road, Ujjain-456010

Phone: 0734 2518989 2513349, Email:raajmedisafe@gmail.com,

Website: www.raajmedisafeindia.com

August 08, 2023

To,  
The Corporate Relationship Dept.  
BSE Ltd.  
Phiroze Jeejeebhoy Towers,  
Dalal Street  
Mumbai -400001  
**Scrip Code: 524502**

Dear Sir,

**Re     UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30,2023.**

Pursuant to clause 33 of the (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:

- a. Unaudited Quarterly Financial Results for the quarter ended June 30, 2023.
- b. Limited review Report on the Unaudited Financial Results for the quarter ended June 30,2023.

The above results have been reviewed by the Audit Committee and taken on record by the Board Directors of the Company in its meeting held on August 08, 2023.

Please take the same on record.

Thanking You,  
Yours faithfully,  
For Raaj Medisafe India Limited

**ARPIT**  
**BANGUR**

Digitally signed  
by ARPIT BANGUR  
Date: 2023.08.08  
16:04:38 +05'30'

Arpit Bangur  
Director  
DIN: 02600716

Encl: As stated

# V.K. LADHA & ASSOCIATES

## CHARTERED ACCOUNTANTS

36 DRAWID MARG, KSHIR SAGAR COLONY, UJJAIN

PH.(0734)2550498-99, Telefax: 0734-4040498 Mobile 98270-81499

E-mail id: [ladha@vkladha.com](mailto:ladha@vkladha.com)

website: [www.vkladha.com](http://www.vkladha.com)



### Report on Review of Interim Financial Information

To,  
Board of Directors of  
Raaj Medisafe India Limited  
75/2 and 3, Industrial Area Maxi Road, Ujjain 456010

We have reviewed the accompanying statement of Standalone unaudited Financial Results of the **Raaj Medisafe India Limited (CIN L33112MP1985PLCC003039) for the period ended 30.06.2023** being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) regulation 2015. This statement is the responsibility of the company's management and has been approved by the Board of Directors in charge. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Engagements to review Financial Statements" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, as supplemented by Notes forming part of accounts, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Ujjain  
Date : 08/08/2023  
UDIN: 23071501BGSGRD2836

For V.K. Ladha & Associates  
Chartered Accountants  
Firm Registration No. 002301C



CA V. K. Ladha  
(Partner)  
Membership No.: 076989

**RAAJ MEDISAFE INDIA LIMITED**
**CIN - L33112MP1985PLC003039**
**Reg. Off. : 75/2 and 3 Industrial Area Maksi Road Ujjain 456010**
**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2023**

Statement of Standalone Results		Rs. In lakhs (Except Earning per Share)			
Particulars		Quarter Ended			Year Ended
		30.06.2023	31.03.2023	30.06.2022	31.03.2023
		Unaudited	Audited	Unaudited	Audited
1		2	3	4	5
<b>1</b>	<b>REVENUE FROM OPERATIONS</b>				
	(a) Income from Operations (Sales of Products)	1,051.85	966.19	1,018.91	3,862.31
	(b) Other Operating Income	-	-	-	-
<b>2</b>	<b>OTHER INCOME</b>	0.54	0.54	0.47	2.22
<b>3</b>	<b>Total Income (1+2)</b>	<b>1,052.39</b>	<b>966.73</b>	<b>1,019.37</b>	<b>3,864.54</b>
<b>4</b>	<b>EXPENSES</b>				
	(a) Cost of Material Consumed	804.88	629.81	769.72	2,747.57
	(b) Purchases of Stock in Trade	-	-	-	-
	(c) Change in Inventory of Finished Goods, Work in Progress and Stock in Trade	(48.83)	21.86	3.86	(61.01)
	(d) Employee Benefits Expense	70.38	78.38	61.09	269.57
	(e) Finance Cost	39.15	31.22	22.01	110.89
	(f) Depreciation And Amortisation Expense	19.53	18.58	19.04	75.21
	(g) Other Expenses	103.85	87.06	82.35	345.07
	Manufacturing, Office and Admin. Expenses			-	
	<b>Total Expenses</b>	<b>988.96</b>	<b>866.91</b>	<b>958.06</b>	<b>3,487.30</b>
<b>5</b>	<b>Profit/(Loss) before exceptional items and tax (3-4)</b>	<b>63.43</b>	<b>99.82</b>	<b>61.31</b>	<b>377.23</b>
<b>6</b>	<b>Exceptional Items</b>	<b>0.01</b>	<b>(0.80)</b>	<b>0.02</b>	<b>0.06</b>
<b>7</b>	<b>Profit/(Loss) from ordinary activities before tax (5-6)</b>	<b>63.42</b>	<b>100.62</b>	<b>61.29</b>	<b>377.18</b>
<b>8</b>	<b>Tax Expenses</b>				
	(1) Current Tax	-	63.13	-	63.13
	(2) Income Tax Paid for earlier Years	-	0.80	-	0.80
	(3) Deferred Tax	-	(19.73)	-	(19.73)
<b>9</b>	<b>Net Profit/(Loss) for the period (7-8)</b>	<b>63.42</b>	<b>56.42</b>	<b>61.29</b>	<b>332.98</b>
<b>10</b>	<b>Other Comprehensive Income</b>				
	A (i) Items that will not be reclassified to profit or loss	-	1.09	-	1.09
	(ii) tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) tax relating to items that will be reclassified to profit or loss	-	-	-	-
<b>11</b>	<b>Total Comprehensive Income for the period (9+10)</b>	<b>63.42</b>	<b>57.51</b>	<b>61.29</b>	<b>334.06</b>
<b>12</b>	<b>Paid-up equity share capital</b>	<b>1,090.36</b>	<b>1,090.30</b>	<b>1,090.20</b>	<b>1,090.30</b>
	(Face Value Rs. 10 Per Share)				
<b>13</b>	<b>Reserves excluding Revaluation Reserves</b>	<b>(341.22)</b>	<b>(341.22)</b>	<b>(675.28)</b>	<b>(341.22)</b>
<b>14</b>	<b>Earnings per share (of 10/- each) (not annualised) After CI:</b>				
	(a) Basic	0.58	0.53	0.56	3.06
	(b) Diluted	0.58	0.53	0.56	3.06
<b>See accompanying note to the financial results</b>					

**Notes:-**

1	The aforesaid Unaudited Standalone Financial Results were reviewed by the Audit Committee and approved at the meeting of Board of Directors of company held on 8th Aug 2023. The Statutory Auditors of the the Company have carried out Limited Review of the above Results.
2	Previous year's figures have been regrouped or re-arranged wherever necessary.
3	This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practises and policies to the extent applicable.
4	The Segment Reporting is not applicable for quarter ended June 30, 2023.

Place :- Ujjain  
Dated :- 08/08/2023

For & On behalf of Board of Directors  
For Raaj Medisafe India Limited

**ARPIT  
BANGUR**

Digitally signed  
by ARPIT BANGUR  
Date: 2023.08.08  
16:05:29 +05'30'

Arpit Bangur  
Chairman  
(DIN-02600716)